Brainstorm Cell Therapeutics BCLI Stock
Brainstorm Cell Therapeutics Price Chart
Brainstorm Cell Therapeutics BCLI Financial and Trading Overview
| Brainstorm Cell Therapeutics stock price | 0.91 USD |
| Previous Close | 1.03 USD |
| Open | 1.01 USD |
| Bid | 0.93 USD x 200000 |
| Ask | 0.99 USD x 300000 |
| Day's Range | 0.91 - 1.01 USD |
| 52 Week Range | 0.46 - 1.69 USD |
| Volume | 8.86K USD |
| Avg. Volume | 17.64K USD |
| Market Cap | 10.92M USD |
| Beta (5Y Monthly) | 0.216 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.85 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
BCLI Valuation Measures
| Enterprise Value | 13.01M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.1511627 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.491 |
Trading Information
Brainstorm Cell Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.216 |
| 52-Week Change | -12.50% |
| S&P500 52-Week Change | 20.36% |
| 52 Week High | 1.69 USD |
| 52 Week Low | 0.46 USD |
| 50-Day Moving Average | 0.83 USD |
| 200-Day Moving Average | 0.72 USD |
BCLI Share Statistics
| Avg. Volume (3 month) | 17.64K USD |
| Avg. Daily Volume (10-Days) | 51.83K USD |
| Shares Outstanding | 11.03M |
| Float | 9.92M |
| Short Ratio | 1.27 |
| % Held by Insiders | 10.26% |
| % Held by Institutions | 0% |
| Shares Short | 604.46K |
| Short % of Float | 6.46% |
| Short % of Shares Outstanding | 5.96% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -257.45% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -8726000 USD |
| Net Income Avi to Common (ttm) | -9570000 USD |
| Diluted EPS (ttm) | -0.82 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 15K USD |
| Total Cash Per Share (mrq) | 0.001 USD |
| Total Debt (mrq) | 1.49M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.016 |
| Book Value Per Share (mrq) | -0.998 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -6664000 USD |
| Levered Free Cash Flow (ttm) | -3324250 USD |
Profile of Brainstorm Cell Therapeutics
| Country | United States |
| State | NY |
| City | New York |
| Address | 1325 Avenue of Americas |
| ZIP | 10019 |
| Phone | 201 488 0460 |
| Website | https://www.brainstorm-cell.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 19 |
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of Alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Q&A For Brainstorm Cell Therapeutics Stock
What is a current BCLI stock price?
Brainstorm Cell Therapeutics BCLI stock price today per share is 0.91 USD.
How to purchase Brainstorm Cell Therapeutics stock?
You can buy BCLI shares on the OTC Markets OTCQB exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Brainstorm Cell Therapeutics?
The stock symbol or ticker of Brainstorm Cell Therapeutics is BCLI.
Which industry does the Brainstorm Cell Therapeutics company belong to?
The Brainstorm Cell Therapeutics industry is Biotechnology.
How many shares does Brainstorm Cell Therapeutics have in circulation?
The max supply of Brainstorm Cell Therapeutics shares is 11.03M.
What is Brainstorm Cell Therapeutics Price to Earnings Ratio (PE Ratio)?
Brainstorm Cell Therapeutics PE Ratio is now.
What was Brainstorm Cell Therapeutics earnings per share over the trailing 12 months (TTM)?
Brainstorm Cell Therapeutics EPS is -0.85 USD over the trailing 12 months.
Which sector does the Brainstorm Cell Therapeutics company belong to?
The Brainstorm Cell Therapeutics sector is Healthcare.
Brainstorm Cell Therapeutics BCLI included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26244.17 USD — |
+0.53
|
3.99B USD — | 26041.13 USD — | 26316.81 USD — | — - | 3.99B USD — |
|
US Tech Capital Market Composite
RCMP
US
|
140.69 USD — |
+0.28
|
— — | 138.5 USD — | 141.42 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1251.8 USD — |
+0.85
|
— — | 1233.72 USD — | 1252.43 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
32400.65 USD — |
+0.6
|
— — | 32125.24 USD — | 32465.34 USD — | — - | — — |
- {{ link.label }} {{link}}